RecruitingNot ApplicableNCT05724992

Familial Pancreatic Cancer PROPHilation Program in Italy

Standardised Genetic Profiling of Subjects Belonging to the Italian Multicenter Registry of Prospective Surveillance of Subjects at Genetic Risk of Pancreatic Cancer

Sponsor

Associazione Italiana per lo Studio del Pancreas

Enrollment

3,000 participants

Start Date

Dec 20, 2022

Study Type

INTERVENTIONAL

Conditions

Candidates for Hereditary Pancreatic Cancer Testing

Summary

The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only. Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test. Up to 3,000 participants will be enrolled in this study.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Inclusion Criteria3

Being enrolled on the IRFARPC registry
Having familiarity for pancreatic cancer (according to the IRFARPC criteria, Capurso et al. Dig Liv Dis, 2020)
Willingness to participate in saliva-swab-based genetic testing

Exclusion Criteria1

\- Already known genetic mutation

Interventions

GENETICSaliva swab testing

41 pancreatic cancer predisposition genes will be tested through a saliva-based swab

Locations(1)

Chirurgia generale e del Pancreas Azienda Ospedaliera Universitaria Integrata

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05724992